Edition:
United States

Astellas Pharma Inc (ALPMF.PK)

ALPMF.PK on OTC Markets Group

12.75USD
26 May 2017
Change (% chg)

$0.14 (+1.11%)
Prev Close
$12.61
Open
$12.75
Day's High
$12.75
Day's Low
$12.75
Volume
601,000
Avg. Vol
53,153
52-wk High
$18.50
52-wk Low
$12.50

Select another date:

Tue, May 16 2017

BRIEF- Astellas Pharma completes acquisition of Ogeda SA in Belgium

* Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17

BRIEF- Astellas Pharma to discontinue ASP8273 treatment and close randomization for clinical study protocol 8273-CL-0302

* Says it announced the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib

BRIEF-Astellas Pharma says transfer of 16 Long-Listed Products in Japan to LTL Pharma

* Says Astellas and LTL Pharma Co., Ltd.confirmed the relevant closing conditions are met on April 28 to allow the transfer of the assets related to Astellas’ 16 long-listed products in Japan to LTL Pharma

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31

BRIEF-Astellas Pharma to acquire Ogeda SA

* under agreement, Astellas has agreed to pay up to a total of eur 800 million

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

BRIEF-Lupin's unit Kyowa and Astellas enter into agreement

* Says Astellas and Lupin s subsidiary Kyowa enter into an agreement

BRIEF-Astellas says to buy back up to 1.43 pct of own shares worth 50 bln yen

* to buy back up to 1.43 percent of own shares worth 50 billion yen Further company coverage:

Select another date:

More From Around the Web